Swallow whole with a glass of water. Do not chew. H2 blockers decrease the production of new stomach acid by blocking the histamine receptors that trigger stomach acid production, thereby providing lasting relief. Calcium carbonate and magnesium hydroxide are the salt forms of elemental or base calcium and magnesium. The rationale for this warning is that trouble swallowing may indicate a more severe underlying disease state than just heartburn alone.
It is recommended that if you have trouble swallowing, you should consult your physician before using this product. Gluten or gluten-containing grains are not ingredients in the product. However, we do not currently test our final products for gluten, and we cannot confirm that the product or any ingredients in the product are free of gluten. We strongly recommend that if you have any form of gluten intolerance or sensitivity, you should consult your doctor before taking any medication, since he or she is most familiar with your medical history.
Our Products. Understanding Heartburn. Compare Heartburn Treatments. Compare H2 Blockers VS. Antacids Vs. QA Text:. Fosamprenavir: Moderate The coadministration of fosamprenavir with H2-blockers decreases amprenavir plasma concentrations. Use these drugs together with caution as amprenavir plasma concentrations may be decreased, which could lead to loss of virologic response and possible viral resistance to fosamprenavir. Gefitinib: Major Avoid coadministration of famotidine with gefitinib if possible due to decreased exposure to gefitinib, which may lead to reduced efficacy.
If concomitant use is unavoidable, take gefitinib 6 hours after the last dose or 6 hours before the next dose of famotidine. Gefitinib exposure is affected by gastric pH. Glipizide; Metformin: Minor Famotidine may decrease the renal clearance of metformin secondary to competition for renal tubular transport systems. Glyburide; Metformin: Minor Famotidine may decrease the renal clearance of metformin secondary to competition for renal tubular transport systems.
Infigratinib: Moderate Separate the administration of infigratinib and H2-receptor antagonists if concomitant use is necessary. Coadministration may decrease infigratinib exposure resulting in decreased efficacy. Administer infigratinib two hours before or ten hours after an H2-receptor antagonist. Iron: Minor The bioavailability of oral iron salts is influenced by gastric pH, and the concomitant administration of H2-blockers can decrease iron absorption.
The non-heme ferric form of iron needs an acidic intragastric pH to be reduced to ferrous and to be absorbed. Iron salts and polysaccharide-iron complex provide non-heme iron. H2-blockers have long-lasting effects on the secretion of gastric acid and thus, increase the pH of the stomach. The increase in intragastric pH can interfere with the absorption of iron salts. Itraconazole: Moderate When administering H2-blockers with the mg itraconazole capsule and mg itraconazole tablet formulations, systemic exposure to itraconazole is decreased.
Conversely, exposure to itraconazole is increased when H2-blockers are administered with the 65 mg itraconazole capsule. Administer H2-blockers at least 2 hours before or 2 hours after the mg capsule or mg tablet. Monitor for increased itraconazole-related adverse effects if H2-blockers are administered with itraconazole 65 mg capsules.
Ketoconazole: Major Ketoconazole requires an acidic pH for absorption. Medications that increase gastric pH or decrease acid output can cause a notable decrease in the bioavailability of ketoconazole.
Medications that have this effect are antacids, antimuscarinics, histamine H2-blockers, and proton pump inhibitors PPIs. Except for antacids, these medications have a prolonged duration of action, and staggering their time of administration with ketoconazole by several hours may not prevent the drug interaction.
An alternative imidazole antifungal should be chosen if any of these gastrointestinal medications are required. If these drugs must be coadministered, administer ketoconazole tablets with an acidic beverage and closely monitor for breakthrough infection. Lansoprazole; Naproxen: Moderate The enteric-coated, delayed-release naproxen tablets are designed to dissolve at a pH of 6 or greater.
Ledipasvir; Sofosbuvir: Major Solubility of ledipasvir decreases as gastric pH increases; thus, coadministration of ledipasvir; sofosbuvir with H2-blockers may result in lower ledipasvir plasma concentrations. Ledipasvir; sofosbuvir can be administered with H2-blockers if given simultaneously or separated by 12 hours.
The H2-blocker dose should not exceed a dose that is comparable to famotidine 40 mg twice daily. Lidocaine: Moderate Concomitant use of systemic lidocaine and famotidine may increase lidocaine plasma concentrations by decreasing lidocaine clearance and therefore prolonging the elimination half-life.
Lidocaine; Prilocaine: Moderate Concomitant use of systemic lidocaine and famotidine may increase lidocaine plasma concentrations by decreasing lidocaine clearance and therefore prolonging the elimination half-life.
Linagliptin; Metformin: Minor Famotidine may decrease the renal clearance of metformin secondary to competition for renal tubular transport systems.
Mefloquine: Moderate H2-blockers may increase plasma concentrations of mefloquine. Patients on chronic mefloquine therapy might be at increased risk of adverse reactions, especially patients with a neurological or psychiatric history. In a small study involving 6 healthy subjects and 6 peptic ulcer patients, cimetidine increased the Cmax and AUC of mefloquine.
In the study, the pharmacokinetics of mefloquine were determined after receiving a single oral mefloquine mg dose alone and after 3-days of cimetidine mg PO twice daily. In both healthy subjects and peptic ulcer patients, Cmax was increased The AUC was increased by Elimination half-life, total clearance, and volume of distribution were not significantly affected.
An increase in adverse reactions was not noted. Metformin: Minor Famotidine may decrease the renal clearance of metformin secondary to competition for renal tubular transport systems. Metformin; Repaglinide: Minor Famotidine may decrease the renal clearance of metformin secondary to competition for renal tubular transport systems. Metformin; Rosiglitazone: Minor Famotidine may decrease the renal clearance of metformin secondary to competition for renal tubular transport systems.
Metformin; Saxagliptin: Minor Famotidine may decrease the renal clearance of metformin secondary to competition for renal tubular transport systems. Metformin; Sitagliptin: Minor Famotidine may decrease the renal clearance of metformin secondary to competition for renal tubular transport systems. Naproxen: Moderate The enteric-coated, delayed-release naproxen tablets are designed to dissolve at a pH of 6 or greater.
Naproxen; Esomeprazole: Moderate The enteric-coated, delayed-release naproxen tablets are designed to dissolve at a pH of 6 or greater. Naproxen; Pseudoephedrine: Moderate The enteric-coated, delayed-release naproxen tablets are designed to dissolve at a pH of 6 or greater. Neratinib: Major Take neratinib at least 2 hours before the next dose of an H2-blocker or 10 hours after the last dose of an H2-blocker due to decreased absorption and systemic exposure of neratinib; the solubility of neratinib decreases with increasing pH of the GI tract.
Nilotinib: Moderate If concomitant use of these agents is necessary, administer the H2-blocker approximately 10 hours before and approximately 2 hours after the nilotinib dose. Nilotinib displays pH-dependent solubility with decreased solubility at a higher pH. The concomitant use of nilotinib and H2-blockers that elevate the gastric pH may reduce the bioavailability of nilotinib.
In a study in healthy subjects, there was no significant change in nilotinib pharmacokinetics when a single mg nilotinib dose was given 10 hours after and 2 hours prior to famotidine. Octreotide: Moderate Coadministration of oral octreotide with H2-blockers may require increased doses of octreotide. Coadministration of oral octreotide with drugs that alter the pH of the upper GI tract, including H2-blockers, may alter the absorption of octreotide and lead to a reduction in bioavailability.
Pazopanib: Major Avoid coadministration of pazopanib with H2-blockers due to decreased absorption of pazopanib, which may decrease efficacy.
If concomitant administration with a gastric acid-reducing agent is unavoidable, consider the use of a short-acting antacid in place of an H2-blocker; separate administration of the short-acting antacid and pazopanib by several hours to avoid a reduction in pazopanib exposure. Pexidartinib: Moderate Administer pexidartinib 2 hours before or 10 hours after H2-blockers as concurrent administration may reduce pexidartinib exposure.
Pioglitazone; Metformin: Minor Famotidine may decrease the renal clearance of metformin secondary to competition for renal tubular transport systems. Polyethylene Glycol; Electrolytes; Bisacodyl: Minor The concomitant use of bisacodyl tablets with H2-blockers can cause the enteric coating of the bisacody tablet to dissolve prematurely, leading to possible gastric irritation or dyspepsia. Rasagiline: Moderate Monitor for dopaminergic adverse effects during concurrent use of rasagiline and famotidine.
Coadministration may result in increased rasagiline concentrations. A dose reduction of rasagiline may be necessary. Rilpivirine: Moderate Coadministration with famotidine may significantly decrease rilpivirine plasma concentrations, potentially resulting in treatment failure.
Risedronate: Major Use of H2-blockers with delayed-release risedronate tablets Atelvia is not recommended. Secretin: Major Discontinue use of H2-blockers at least 2 days before administering secretin. Patients who are receiving H2-blockers at the time of stimulation testing may be hyperresponsive to secretin stimulation, falsely suggesting gastrinoma. Selpercatinib: Major Avoid coadministration of selpercatinib with famotidine due to the risk of decreased selpercatinib exposure which may reduce its efficacy.
If concomitant use is unavoidable, take selpercatinib 2 hours before or 10 hours after administration of famotidine. Coadministration with acid-reducing agents decreases selpercatinib plasma concentrations; however, no clinically significant differences in the pharmacokinetics of selpercatinib were observed when given under fasting conditions with multiple daily doses of another H2-receptor antagonist given 10 hours prior to and 2 hours after the selpercatinib dose.
Sofosbuvir; Velpatasvir: Major H2-blockers may be administered simultaneously with or 12 hours apart from velpatasvir. H2-blocker doses should not exceed doses comparable to famotidine 40 mg twice daily.
Velpatasvir solubility decreases as pH increases; therefore, drugs that increase gastric pH are expected to decrease the concentrations of velpatasvir, potentially resulting in loss of antiviral efficacy. Sofosbuvir; Velpatasvir; Voxilaprevir: Major H2-blockers may be administered simultaneously with or 12 hours apart from velpatasvir. Sotorasib: Major Avoid coadministration of sotorasib and gastric acid-reducing agents, such as H2-receptor antagonists.
Coadministration may decrease sotorasib exposure resulting in decreased efficacy. If necessary, sotorasib may be administered 4 hours before or 10 hours after a locally acting antacid. Sumatriptan; Naproxen: Moderate The enteric-coated, delayed-release naproxen tablets are designed to dissolve at a pH of 6 or greater.
Thalidomide: Moderate Thalidomide and other agents that slow cardiac conduction such as H2-blockers should be used cautiously due to the potential for additive bradycardia. Theophylline, Aminophylline: Minor Aminophylline is a prodrug of theophylline, and is primarily metabolized in the liver by the CYP1A2 isoenzyme. In general, famotidine does not interact with aminophylline and does not affect theophylline levels in most patients. One small study documented a significant decrease in theophylline clearance after therapy with famotidine.
Be alert for any evidence of interaction, and monitor the patients aminophylline therapy as per standard of care or if side effects are reported. In general, famotidine does not interact with theophylline and does not affect theophylline levels in most patients.
Be alert for any evidence of interaction, and monitor the patients theophylline therapy as per standard of care or if side effects are reported. If possible, avoid the concurrent use of tizanidine with other CYP1A2 inhibitors. Famotidine is a weak CYP1A2 inhibitor. Concurrent use could lead to substantial increases in tizanidine blood concentrations.
If concurrent use cannot be avoided, initiate tizanidine therapy with the 2 mg dose and increase in 2 to 4 mg increments daily based on patient response to therapy. Discontinue tizanidine if hypotension, bradycardia, or excessive drowsiness occur. Warfarin: Moderate Closely monitor the INR if coadministration of warfarin with famotidine is necessary as concurrent use may increase the exposure of warfarin leading to increased bleeding risk.
The S-enantiomer of warfarin exhibits 2 to 5 times more anticoagulant activity than the R-enantiomer, but the R-enantiomer generally has a slower clearance. Famotidine competitively inhibits the binding of histamine to H2-receptors on the gastric basolateral membrane of parietal cells, reducing basal and nocturnal gastric acid secretions.
The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin. Famotidine reduces the total volume of gastric juice, thus indirectly decreasing pepsin secretion. The drug does not appear to alter gastric motility, gastric emptying, esophageal pressures, biliary secretions, or pancreatic secretions.
Famotidine may aid in gastromucosal healing, and it may protect the mucosa from the irritant effects caused by aspirin and nonsteroidal antiinflammatory agents.
Famotidine is administered orally and parenterally. There is no cumulative effect with repeat doses; plasma concentrations after multiple doses are similar to those after single doses. Famotidine undergoes minimal first-pass metabolism. The S-oxide metabolite is the only 1 identified in humans. Famotidine elimination half-life is 2. In vitro studies also indicate that famotidine is a substrate for human organic anion transporter OAT 1 and 3 and an inhibitor of multidrug and toxin extrusion protein 1 MATE Famotidine tablets, oral suspension, and orally disintegrating tablets are bioequivalent.
Food may slightly increase and antacids may slightly decrease the bioavailability of famotidine; however, the effects are considered clinically insignificant. The onset of action is usually within 1 hour after oral administration with maximum effects occurring within 1 to 3 hours depending on the dose.
The duration of action is roughly 10 to 12 hours. PDR Search. Required field. Your Name Your name is required. Recipient's Email Separate multiple email address with a comma Please enter valid email address Recipient's email is required. Taking it again could be fatal cause death. For people with moderate or severe kidney disease: If you have kidney problems, you may not be able to clear this drug from your body. This may increase the levels of this drug in your body.
The increased levels may cause more side effects, such as confusion and an irregular heart rhythm called QT prolongation. Research in animals has not shown a risk to the fetus when the mother takes the drug.
This drug should only be used in pregnancy if clearly needed. For women who are breastfeeding: Famotidine may pass into breast milk and may cause side effects in a child who is breastfed.
Talk to your doctor if you breastfeed your child. You may need to decide whether to stop breastfeeding or stop taking this medication. For seniors: The kidneys of older adults may not work as well as they used to. Famotidine oral tablet is used for long-term treatment of Zollinger-Ellison syndrome and maintaining healing of ulcers. Famotidine oral tablet is used for short-term treatment of gastroesophageal reflux disease GERD and duodenal and gastric ulcers.
For this drug to work well, a certain amount needs to be in your body at all times. If you take too much: You could have dangerous levels of the drug in your body. Symptoms of an overdose of this drug can include:. If your symptoms are severe, call or go to the nearest emergency room right away. What to do if you miss a dose: Take your dose as soon as you remember. But if you remember just a few hours before your next scheduled dose, take only one dose.
Never try to catch up by taking two doses at once. This could result in dangerous side effects. How to tell if the drug is working: You should have less pain and your symptoms should improve. Keep them away from light. A prescription for this medication is refillable. You should not need a new prescription for this medication to be refilled.
Your doctor will write the number of refills authorized on your prescription. Certain foods and beverages may irritate your stomach. This irritation could make your symptoms worse. Your doctor may suggest that you avoid spicy, acidic, and fatty foods while you take this drug. Acidic foods include tomatoes and citrus fruits. They may also ask you to avoid beverages with caffeine. Many insurance companies require a prior authorization for this drug. This means your doctor will need to get approval from your insurance company before your insurance company will pay for the prescription.
There are other drugs available to treat your condition. Some may be better suited for you than others. Talk to your doctor about other drug options that may work for you. Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up-to-date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional.
You should always consult your doctor or other healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
0コメント